S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
NASDAQ:CRDF

Cardiff Oncology (CRDF) Stock Price, News & Analysis

$5.26
-0.49 (-8.52%)
(As of 02:34 PM ET)
Today's Range
$5.22
$5.73
50-Day Range
$1.47
$5.91
52-Week Range
$0.94
$6.42
Volume
562,295 shs
Average Volume
1.66 million shs
Market Capitalization
$235.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Cardiff Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
97.0% Upside
$10.50 Price Target
Short Interest
Bearish
6.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Cardiff Oncology in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.98) to ($1.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.12 out of 5 stars

Medical Sector

854th out of 939 stocks

Biological Products, Except Diagnostic Industry

144th out of 154 stocks

CRDF stock logo

About Cardiff Oncology Stock (NASDAQ:CRDF)

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CRDF Stock Price History

CRDF Stock News Headlines

AI Bubble Now at Critical Mass
Washington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.
REGN Mar 2024 1010.000 put
REGN Mar 2024 982.500 call
CRDF Apr 2024 2.500 call
CRDF Nov 2024 10.000 put
CRDF Apr 2024 5.000 call
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
REGN Mar 2024 992.500 call
Q4 2023 Cardiff Oncology Inc Earnings Call
TD Cowen Sticks to Their Buy Rating for Cardiff Oncology (CRDF)
Cardiff Oncology Earnings Preview
See More Headlines
Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CRDF
Fax
N/A
Employees
31
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$14.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+82.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-41,440,000.00
Net Margins
-8,492.01%
Pretax Margin
-8,492.01%

Debt

Sales & Book Value

Annual Sales
$490,000.00
Book Value
$1.56 per share

Miscellaneous

Free Float
41,862,000
Market Cap
$256.91 million
Optionable
Optionable
Beta
1.72

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

CRDF Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardiff Oncology stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings
or view top-rated stocks.

What is Cardiff Oncology's stock price target for 2024?

2 analysts have issued 1 year price objectives for Cardiff Oncology's shares. Their CRDF share price targets range from $7.00 to $14.00. On average, they predict the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 97.0% from the stock's current price.
View analysts price targets for CRDF
or view top-rated stocks among Wall Street analysts.

How have CRDF shares performed in 2024?

Cardiff Oncology's stock was trading at $1.48 at the start of the year. Since then, CRDF shares have increased by 260.1% and is now trading at $5.33.
View the best growth stocks for 2024 here
.

Are investors shorting Cardiff Oncology?

Cardiff Oncology saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,810,000 shares, an increase of 144.3% from the February 29th total of 1,150,000 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is currently 1.8 days.
View Cardiff Oncology's Short Interest
.

When is Cardiff Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRDF earnings forecast
.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05. The company earned $0.16 million during the quarter, compared to analysts' expectations of $0.08 million. Cardiff Oncology had a negative net margin of 8,492.01% and a negative trailing twelve-month return on equity of 50.13%.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.28%), Vanguard Group Inc. (4.28%), Creative Planning (0.06%), Virtu Financial LLC (0.05%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gary W Pace, James E Levine, Lale White, Mark Erlander and Renee P Tannenbaum.
View institutional ownership trends
.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRDF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners